New Pfizer RSV Vaccine Linked To Premature Births in Pregnant Women
The first post-authorization safety analysis of Pfizer’s Abrysvo RSV vaccine
found the average time between vaccination and preterm birth was three days.
Two-thirds of reported cases occurred within a week.
A new preprint study shows a statistically significant safety signal for preterm birth associated with Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo.
The first post-authorization safety analysis of Pfizer’s RSV vaccine — RSV prefusion F protein (RSVPreF) — found the average time between vaccination and preterm birth was three days.
Two-thirds of reported cases occurred within a week.
“This study highlights ongoing concern about preterm birth among pregnant individuals following RSVPreF vaccination,” the authors wrote.
Canadian researchers at the University of Ottawa School of Epidemiology and Public Health assessed all adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) database following RSV immunization between Sept. 1, 2023, and Feb. 23, 2024.